Dana Pizzuti - 01 Dec 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: Chief Med and Dev Officer
Issuer ticker: CRNX
Reported as of: 01 Dec 2025
Net transaction value: -$140,650
SEC form: 4
Accepted by SEC: 03 Dec 2025, 16:28:31 UTC
Prior SEC filing: 05 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Tobin Schilke, as attorney-in-fact

Key filing fact

Dana Pizzuti filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 03 Dec 2025.

Key facts

This page summarizes Dana Pizzuti's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Dec 2025, 16:28.

Change

Previous filing in this sequence was filed on 05 Nov 2025.
Current net transaction value: -$140,650.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001948238 Primary reporting owner

Pizzuti Dana

Relationship: Chief Med and Dev Officer
Address: C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
Signature: /s/ Tobin Schilke, as attorney-in-fact
Signature date: 03 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Options Exercise

Transaction value: $84,450
Shares: +5,000
Change %: +7.5%
Price: $16.89
Shares after: 71,837
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F1

CRNX transaction

Common Stock

Sale

Transaction value: $225,100
Shares: -5,000
Change %: -7%
Price: $45.02
Shares after: 66,837
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRNX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -5,000
Change %: -6.8%
Price: $0.000000
Shares after: 69,042
Date: 01 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $16.89
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Includes 567 shares acquired under the Issuer's Employee Stock Purchase Plan.

Footnote F2

The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.

Footnote F3

The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $45.02 per share. The range of sale prices on the transaction date was $44.59 to $45.51. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Footnote F4

The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.